What drives a clinical trial investigator? The chance to support progress in science for patients. | Regeneron

🌟 Did you know? Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer, with an estimated 1.8 million cases diagnosed each year in the U.S. – and continues to be on the rise. People with CSCC with a high risk of recurrence have a greater chance of the cancer coming back after treatment, which is why identification of high-risk features is so important. Stay informed, prioritize skin health and consult a healthcare provider for regular check-ups. ✅ | Regeneron

We’re excited to share that the U.S. FDA has approved our medicine as an adjuvant treatment for people with cutaneous squamous cell carcinoma (#CSCC) with high risk of recurrence after surgery and radiation. We believe the CSCC community deserves more from their care, and we remain committed to further advancing research that addresses unmet needs and makes a meaningful difference for people living with high-risk CSCC. Learn more: https://bit.ly/42zjjX3 | Regeneron

À seulement 18 ans, Matteo Paz remporte le prestigieux concours Regeneron Science Talent Search pour sa découverte de 1,5 million d’objets cachés dans l’univers. Abonne-toi pour ➕ d’initiatives positives ! 🍀 | Le Média Positif